Canopy Growth Corp vs Invesco DB Oil Fund — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while Invesco DB Oil Fund trades at $20.95. The key difference: Invesco DB Oil Fund is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | DBO | |
|---|---|---|
Market Cap | $421.10M | — |
Sector | Health | Commodities - Energy |
52-Week High | $1.92 | $23.80 |
52-Week Low | $0.86 | $11.98 |
Enterprise Value | $378.55M | — |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
DBO trades at $20.88, up 0.14% today, with a bullish technical signal driven by moving averages and neutral oscillators. Recent news highlights oil market volatility due to Middle East supply disruptions and OPEC demand forecast cuts. The stock lacks disclosed financial ratios, limiting fundamental clarity amid sector-wide data reliability concerns.
Outlook hinges on oil price stability and company-specific updates, with upside potential from supply shocks but risks from demand weakness and geopolitical uncertainty. Investors await earnings and guidance for valuation anchors.
Trailing returns across standard periods
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →